Positive Results from Purple Biotech's CM24 Study
The latest results from Purple Biotech Ltd. highlight the promising efficacy of their oncology drug CM24 in treating second-line pancreatic ductal adenocarcinoma (PDAC). The clinical trial tested CM24, a humanized monoclonal antibody designed to block the CEACAM1 protein, in combination with nivolumab and standard chemotherapy regimens against a control group receiving chemotherapy alone. Results indicate a notable enhancement across all efficacy endpoints evaluated.
Significant Improvements in Efficacy Endpoints
Final data from the trial revealed that patients treated with CM24 alongside nivolumab and the chemotherapy regimen Nal-IRI/5FU/LV experienced an impressive 79% reduction in the risk of death compared to the control group. The hazard ratio for overall survival (OS) stood at 0.21, with a median OS improvement of 5.1 months. Additionally, there was over a 90% reduction in the risk of progression or death, with a median progression-free survival (PFS) improvement of 2.9 months. The overall response rate (ORR) also showcased remarkable results, with 50% of treated patients showing positive responses against none in the control group.
Future Plans for Clinical Studies
The encouraging findings have spurred plans for a Phase 2b clinical study targeting multiple selected indications, particularly focusing on patients identified through biomarker analysis. The study aims to replicate and expand upon the positive responses observed, creating pathways for potential treatments of various malignancies that express CEACAM1.
Insights from Experts
Gil Efron, CEO of Purple Biotech, expressed enthusiasm regarding the trials' results and the potential to identify a biomarker-enriched patient population that could enhance CM24's efficacy. Michael Cecchini, M.D., a key researcher, reinforced the importance of these findings, emphasizing the need for new and effective therapies in late-stage metastatic PDAC.
Clinical Study Overview
The randomized Phase 2 study incorporated 63 patients across 18 centers and investigated the effects of CM24 in synergy with nivolumab versus standard chemotherapy alone. Importantly, the investigation observed that in the experimental arm, CA19-9—a validated PDAC biomarker—exhibited a consistent decrease, highlighting treatment efficacy.
Transparency on Safety and Tolerability
Regarding safety, the CM24+nivolumab+Nal-IRI/5FU/LV combination was well tolerated by patients, displaying a manageable profile of adverse events. This result is promising as it gauges the treatment's overall acceptability among affected patients.
About Purple Biotech Ltd.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is committed to developing first-in-class therapies that address tumor immune evasion and drug resistance. The comprehensive oncology pipeline includes CM24, along with other innovative treatments like NT219 and IM1240. Each of these therapies targets distinct pathways that facilitate tumor growth and survival, aiming for significant advancements in cancer care.
Frequently Asked Questions
What is CM24, and what does it target?
CM24 is a humanized monoclonal antibody that blocks CEACAM1, a protein implicated in tumor immunity and metabolism, primarily in cancer treatments.
How did CM24 perform in the clinical trial?
The trial demonstrated a substantial reduction in the risk of death, improved overall survival and progression-free survival rates, and high treatment response rates.
What are the future plans following the trial's results?
A new Phase 2b clinical study is set to explore CM24's effectiveness across multiple cancer types, focusing on biomarker-enriched populations.
Who is leading the clinical research?
Dr. Michael Cecchini from Yale Cancer Center serves as a principal investigator in this promising study.
What is the significance of the study findings?
The findings offer a pathway towards new therapeutic options for patients suffering from difficult-to-treat cancers, especially PDAC.
